Preliminary observations on the efficacy of a recombinant multistage Plasmodium falciparum vaccine in Aotus nancymai monkeys

Am J Trop Med Hyg. 2005 Oct;73(4):686-93.

Abstract

A vaccine trial was conducted to determine the efficacy of a multicomponent candidate vaccine, FALVAC-1, against Plasmodium falciparum in Aotus nancymai monkeys. After two immunizations, animals were challenged intravenously with parasites of the Vietnam Oak Knoll (FVO) strain of P. falciparum. The primary outcome was to determine the protective response of the monkeys to immunization with the FALVAC-1 antigen produced in baculovirus when combined with different adjuvants (alum, QS-21, ASO2a, CRL1005/oil, and CRL1005/saline) as compared with FALVAC-1 with FCA/FIA and antigen alone. When compared with the monkeys immunized with FALVAC-1 alone, FALVAC-1 with FCA/FIA reduced the mean parasite count (to Day 11), reduced the mean accumulated parasitemia (through Day 11), and extended the number of days to treatment. None of the other 5 antigen-adjuvant combinations were able to provide discernable levels of protection based on log(parasitemia) and log(cumulative parasitemia) to Day 11.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Alum Compounds / administration & dosage
  • Animals
  • Aotidae
  • Disease Models, Animal
  • Drug Combinations
  • Female
  • Freund's Adjuvant / administration & dosage
  • Freund's Adjuvant / immunology
  • Hematocrit
  • Immunization Schedule
  • Lipid A / administration & dosage
  • Lipid A / analogs & derivatives
  • Lipid A / immunology
  • Malaria Vaccines / administration & dosage*
  • Malaria Vaccines / adverse effects
  • Malaria Vaccines / genetics
  • Malaria Vaccines / immunology
  • Malaria, Falciparum / prevention & control*
  • Male
  • Plasmodium falciparum / immunology*
  • Plasmodium falciparum / pathogenicity
  • Polymers / administration & dosage
  • Saponins / administration & dosage
  • Saponins / immunology
  • Treatment Outcome
  • Vaccines, Synthetic / administration & dosage*
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology

Substances

  • ASO2A adjuvant
  • Adjuvants, Immunologic
  • Alum Compounds
  • CRL 1005
  • Drug Combinations
  • Lipid A
  • Malaria Vaccines
  • Polymers
  • Saponins
  • Vaccines, Synthetic
  • aluminum sulfate
  • saponin QA-21V1
  • Freund's Adjuvant